WELCOME!

- We will begin shortly.
- Please type your name and email into the chat box for attendance.
- Reminder, we will be recording this session.
- Please mute your line upon entering and chat in your comments or questions.
- Vicki Flanagan will monitor the chat box and call on you to unmute yourself.
- If you have trouble connecting, please email karen.g.lee@hitchcock.org






















Measuring Success

Each core bundle has pre-defined measures

- Process
- Structure
- Outcome

Disaggregation of key metrics by race and ethnicity allows states and hospitals to identify disparities in care and outcomes







Example Bundle Metrics: SUD

Process

- % of pregnant people with OUD who receive MOUD
- Naloxone access [situational surveillance question]

Structure

• Stigma/antibias training for staff


Outcome

- % of neonates with prenatal substance exposure
- Maternal mortality
- Severe maternal morbidity










Possible Data Sources


- NH-MMRC case review identifies key drivers of maternal mortality and antecedent causes
- Hospital discharge data
- Claims data
- Vital records
 - · Perinatal substance exposure
 - · Perinatal complications
 - · Maternal demographics
- Situational surveillance questions: emerging threats/initiatives











Prenatal Substance Exposure 82A. Was the infant monitored for effects of in utero NH Vital Records Data substance exposure? ☐ Yes ☐ No If YES, Type of substance(s): (check all that apply) ☐ opioids ☐ stimulants (amphetamines, methamphetamines, other) **Situational Surveillance** ☐ cocaine Q1: Is there documentation that cannabis □ benzodiazepines access to naloxone (e.g. Narcan) was □ barbiturates discussed with the patient? ☐ alcohol ☐ Yes ☐ nicotine ☐ bath salts ☐ No ☐ Kratom □ Unknown ☐ Other (Specify). Aim: Determine frequency of practice. B. Was the infant identified as being affected by substance misuse or withdrawal symptoms resulting from prenatal drug exposure, or a Fetal Alcohol Spectrum Disorder? The NH Birth Situational Surveillance ☐ Yes ☐ No Narcan/Naloxone discussion question was activated Plan of Safe/Supportive Care at the end of January 2021. 83. Was a Plan of Safe/Supportive Care (POSC) created? ☐ Yes ☐ No The prenatal substance exposure section was added to the NH Facility Worksheet in late April 2020. **Standard Worksheet**

Why a Dashboard?

Timely feedback on frontline improvement work

- Tracks key process and outcome measures
- May be individualized to reflect priority areas for a specific setting
- Can be revised as priorities shift
- Facilitates internal communication about performance
- Allows comparison of shared metrics across a collaborative [benchmarking]







A NH-specific Perinatal Quality Dashboard


Based on vital records and situational surveillance questions

- · Relevant and meaningful to each hospital
- Reflective of current priorities of NH-AIM
- Include a set of core measures shared by all hospitals to allow for benchmarking/collaborative learning
 - Important perinatal quality measures
 - · Capable of presenting data disaggregated by race, ethnicity, and payor









Save the Date

Introducing the revised AIM Patient Safety Bundle for the Care of Pregnant and Postpartum People with Substance Use Disorders

August 12, 2021









Text 603-346-4334

Enter Activity Code: RgjY (Good for this Live Session Only)

Need help? clpd.support@hitchcock.org

Signing in on-line? http://www.d-h.org/clpd-account

Our presenters have no conflicts of interest to disclose.







Let's stay in touch....

Victoria.A.Flanagan@hitchcock.org daisy.j.goodman@hitchcock.org







